Loading
CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells.
CIViC holds 8 clinical evidence items and 0 assertions across 6 variants, naming Crizotinib, Pazopanib, Foretinib and Palbociclib Regimen. Open Targets scores its association with cancer at 0.90 (direct and indirect evidence; datatypes genetic literature 0.82, affected pathway 0.54, literature 1.00, genetic association 0.83, somatic mutation 0.96). IntOGen calls it a driver in 18 cohorts (3 activating, 14 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cutaneous Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma, Stomach Adenocarcinoma.
In plain words · CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
No product in this corpus aims at CDH1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CDH1: RNA tissue enhanced (parathyroid gland 186 nTPM); blood lineage lineage enriched (dendritic cells 5 nTPM); high antibody staining in 26 normal tissues; highest cancer staining colorectal cancer (12 of 12 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Gastric & gastro-oesophageal junction cancer, Breast cancer (all types), Ovarian cancer, Endometrial cancer, Prostate cancer, Bladder & urothelial cancer, Skin cancer (all types) and more); Open Targets associates it with 13 specific cancer types at or above 0.5 (CDH1-related diffuse gastric and lobular breast cancer syndrome, Familial gastric cancer, ovarian cancer, endometrial carcinoma, hereditary breast carcinoma, breast adenocarcinoma and more). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P12830; CIViC gene CDH1; IntOGen CDH1; Human Protein Atlas CDH1 tissue; Open Targets ENSG00000039068 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Mansouri et al, Differentiation, 1988, "Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin". Source.
Sources: HGNC HGNC:1748 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12830 (protein name, function text, keywords and locations (REST API)); CIViC gene CDH1 (8 evidence items, 0 assertions, 6 variants; diseases: Breast Cancer, Cholangiocarcinoma, Stomach Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000039068 (association with cancer (MONDO_0004992) 0.90; per-cancer scores at or above 0.5: colorectal cancer 0.55, gastric cancer 0.84, prostate cancer 0.67, ovarian cancer 0.72, endometrial cancer 0.71, skin cancer 0.58 (GraphQL API, CC0)); IntOGen CDH1 (driver in 18 cohorts (Act 3, LoF 14); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Promotes organisation of radial actin fibre structure and cellular response to contractile forces, via its interaction with AMOTL2 which facilitates anchoring of radial actin fibres to CDH1 junction complexes at the cell membrane. Plays a role in the early stages of desmosome cell-cell junction formation via facilitating the recruitment of DSG2 and DSP to desmosome plaques. Has a potent invasive suppressor role. Location: Cell junction, adherens junction; Cell membrane; Endosome; Golgi apparatus, trans-Golgi network (UniProt). Locus 16q22.1 (HGNC).
RNA: tissue enhanced (parathyroid gland 186 nTPM), detected in many normal tissues. Blood: lineage enriched (dendritic cells 5 nTPM).
Medium: Appendix, Liver, Small intestine.
Medium only: head and neck cancer, renal cancer.
HPA CDH1 tissue · HPA CDH1 pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CDH1" OR ABSTRACT:"CDH1" OR TITLE:"cadherin 1" OR ABSTRACT:"cadherin 1" OR TITLE:"Cadherin-1" OR ABSTRACT:"Cadherin-1" OR TITLE:"uvomorulin" OR ABSTRACT:"uvomorulin" OR TITLE:"CD324" OR ABSTRACT:"CD324") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDH1, not a curated reading list.
Shares Lobular carcinoma in situ (LCIS), Invasive lobular carcinoma of the breast, Breast cancer (all types).
Shares Invasive lobular carcinoma of the breast, Breast cancer (all types).
Shares Lobular carcinoma in situ (LCIS), Breast cancer (all types).
Shares Gastric cancer (KEGG map), Oesophageal cancer, CIViC, IntOGen.
Shares Lobular carcinoma in situ (LCIS), Invasive lobular carcinoma of the breast, Breast cancer (all types).
Shares Invasive lobular carcinoma of the breast, Breast cancer (all types).
Shares Gastric cancer (KEGG map), Gastric & gastro-oesophageal junction cancer.
Shares Invasive lobular carcinoma of the breast, Breast cancer (all types).